InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.

A number of other research analysts also recently commented on NSPR. Piper Sandler reissued an “overweight” rating and set a $4.50 target price on shares of InspireMD in a research report on Tuesday, September 17th. Lake Street Capital began coverage on shares of InspireMD in a research note on Wednesday. They set a “buy” rating and a $5.00 price objective on the stock.

InspireMD Price Performance

NSPR stock opened at $2.95 on Thursday. The company has a market capitalization of $76.94 million, a PE ratio of -3.93 and a beta of 0.98. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.42. The firm’s 50-day moving average is $2.66 and its 200 day moving average is $2.68.

InspireMD (NYSE:NSPR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The business had revenue of $1.81 million for the quarter, compared to analyst estimates of $1.74 million. During the same period last year, the company posted ($0.15) earnings per share. Sell-side analysts forecast that InspireMD will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC bought a new stake in InspireMD, Inc. (NYSE:NSPR) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD as of its most recent SEC filing. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.